| Literature DB >> 34110166 |
Yuwei Zhang1,2, Ayden Malekjahani3,2, Buddhisha N Udugama3,2, Pranav Kadhiresan3,2, Hongmin Chen3,2, Matthew Osborne3,2, Max Franz2, Mike Kucera2, Simon Plenderleith4, Lily Yip4, Gary D Bader2,5,6,7,8, Vanessa Tran9,10, Jonathan B Gubbay9,10, Allison McGeer5,11,12, Samira Mubareka9,4, Warren C W Chan1,3,2,13,14.
Abstract
The ability to rapidly diagnose, track, and disseminate information for SARS-CoV-2 is critical to minimize its spread. Here, we engineered a portable smartphone-based quantum barcode serological assay device for real-time surveillance of patients infected with SARS-CoV-2. Our device achieved a clinical sensitivity of 90% and specificity of 100% for SARS-CoV-2, as compared to 34% and 100%, respectively, for lateral flow assays in a head-to-head comparison. The lateral flow assay misdiagnosed ∼2 out of 3 SARS-CoV-2 positive patients. Our quantum dot barcode device has ∼3 times greater clinical sensitivity because it is ∼140 times more analytically sensitive than lateral flow assays. Our device can diagnose SARS-CoV-2 at different sampling dates and infectious severity. We developed a databasing app to provide instantaneous results to inform patients, physicians, and public health agencies. This assay and device enable real-time surveillance of SARS-CoV-2 seroprevalence and potential immunity.Entities:
Keywords: COVID-19; SARS-CoV-2; database; immunoassay; multiplexing; quantum dot barcodes; real-time monitoring; serological testing; smartphone diagnostics
Mesh：
Year: 2021 PMID： 34110166 DOI： 10.1021/acs.nanolett.1c01280
Source DB: PubMed Journal: Nano Lett ISSN： 1530-6984 Impact factor: 11.189